Alnylam Pharmaceuticals (ALNY) Asset Utilization Ratio (2010 - 2026)
Alnylam Pharmaceuticals posted quarterly Asset Utilization Ratio of 0.85 for Q1 2026, up 101.22% year-on-year from 0.42 in Q1 2025, and up 32.36% on a QoQ basis from 0.64 in Q4 2025.
Alnylam Pharmaceuticals (ALNY) has 17 years of Asset Utilization Ratio data on file, last reported at 0.85 in Q1 2026.
- For the quarter ending Q1 2026, Asset Utilization Ratio rose 101.22% year-over-year to 0.85; the trailing twelve-month figure through Mar 2026 stood at 0.85 (up 101.22% YoY), and the FY2025 full-year result was 0.81, up 44.8% from the prior year.
- Asset Utilization Ratio for Q1 2026 stood at 0.85, up from 0.64 in the prior quarter.
- Across five years, Asset Utilization Ratio topped out at 0.85 in Q1 2026 and bottomed at 0.25 in Q1 2022.
- The 5-year median for Asset Utilization Ratio is 0.48 (2023), against an average of 0.46.
- The widest annual swing landed in 2025, when Asset Utilization Ratio decreased 27.77%; it then surged 101.22% in 2026.
- A 5-year view of Asset Utilization Ratio shows it stood at 0.29 in 2022, then jumped by 62.74% to 0.48 in 2023, then gained by 11.67% to 0.53 in 2024, then increased by 20.51% to 0.64 in 2025, then jumped by 32.36% to 0.85 in 2026.
- The last three Asset Utilization Ratio figures came in at 0.85 (Q1 2026), 0.64 (Q4 2025), and 0.56 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 0.60 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 0.47 |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 0.29 |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 0.37 |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 0.85 |
| 10 | Revolution Medicines | 32.39 Bn | 32.39 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 0.85 |
| Dec 31, 2025 | 0.64 |
| Sep 30, 2025 | 0.56 |
| Jun 30, 2025 | 0.43 |
| Mar 31, 2025 | 0.42 |
| Dec 31, 2024 | 0.53 |
| Sep 30, 2024 | 0.51 |
| Jun 30, 2024 | 0.60 |
| Mar 31, 2024 | 0.52 |
| Dec 31, 2023 | 0.48 |
| Sep 30, 2023 | 0.48 |
| Jun 30, 2023 | 0.36 |
| Mar 31, 2023 | 0.33 |
| Dec 31, 2022 | 0.29 |
| Sep 30, 2022 | 0.28 |
| Jun 30, 2022 | 0.26 |
| Mar 31, 2022 | 0.25 |
| Dec 31, 2021 | 0.24 |
| Sep 30, 2021 | 0.21 |
| Jun 30, 2021 | 0.20 |
| Mar 31, 2021 | 0.17 |
| Dec 31, 2020 | 0.15 |
| Sep 30, 2020 | 0.12 |
| Jun 30, 2020 | 0.12 |
| Mar 31, 2020 | 0.12 |
| Dec 31, 2019 | 0.09 |
| Sep 30, 2019 | 0.06 |
| Jun 30, 2019 | 0.04 |
| Mar 31, 2019 | 0.05 |
| Dec 31, 2018 | 0.05 |
| Sep 30, 2018 | 0.05 |
| Jun 30, 2018 | 0.06 |
| Mar 31, 2018 | 0.05 |
| Dec 31, 2017 | 0.05 |
| Sep 30, 2017 | 0.05 |
| Jun 30, 2017 | 0.05 |
| Mar 31, 2017 | 0.05 |
| Dec 31, 2016 | 0.04 |
| Sep 30, 2016 | 0.03 |
| Jun 30, 2016 | 0.02 |
| Mar 31, 2016 | 0.02 |
| Dec 31, 2015 | 0.03 |
| Sep 30, 2015 | 0.04 |
| Jun 30, 2015 | 0.04 |
| Mar 31, 2015 | 0.04 |
| Dec 31, 2014 | 0.05 |
| Sep 30, 2014 | 0.04 |
| Jun 30, 2014 | 0.03 |
| Mar 31, 2014 | 0.05 |
| Dec 31, 2013 | 0.11 |
| Sep 30, 2013 | 0.10 |
| Jun 30, 2013 | 0.11 |
| Mar 31, 2013 | 0.17 |
| Dec 31, 2012 | 0.22 |
| Sep 30, 2012 | 0.25 |
| Jun 30, 2012 | 0.25 |
| Mar 31, 2012 | 0.27 |
| Dec 31, 2011 | 0.28 |
| Sep 30, 2011 | 0.26 |
| Jun 30, 2011 | 0.25 |
| Mar 31, 2011 | 0.25 |
| Dec 31, 2010 | 0.25 |
| Sep 30, 2010 | 0.25 |